AZD 4573
Alternative Names: AZD-4573Latest Information Update: 12 Feb 2025
At a glance
- Originator AstraZeneca Pharmaceuticals
- Class Amides; Antineoplastics; Cyclohexanes; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 07 Dec 2024 Pharmacodynamics data from a preclinical trial in T-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Apr 2024 Pharmacodynamic data from a preclinical study in Colorectal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia presented at the American Association for Cancer Research (AACR-2024 2024)